Literature DB >> 21778212

Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?

Sandra Lassalle1, Véronique Hofman, Marius Ilie, Christelle Bonnetaud, Marie-Pierre Puisségur, Patrick Brest, Céline Loubatier, Nicolas Guevara, Olivier Bordone, Bruno Cardinaud, Kévin Lebrigand, Géraldine Rios, Joseph Santini, Brigitte Franc, Bernard Mari, Abir Al Ghuzlan, Philippe Vielh, Pascal Barbry, Paul Hofman.   

Abstract

The term 'thyroid tumors of uncertain malignant potential' (TT-UMP) was coined by surgical pathologists to define well-differentiated tumors (WDT) showing inconclusive morphological evidence of malignancy or benignity. We have analyzed the expression of microRNA (miRNA) in a training set of 42 WDT of different histological subtypes: seven follicular tumors of UMP (FT-UMP), six WDT-UMP, seven follicular thyroid adenomas (FTA), 11 conventional papillary thyroid carcinomas (C-PTC), five follicular variants of PTC (FV-PTC), and six follicular thyroid carcinomas (FTC), which led to the identification of about 40 deregulated miRNAs. A subset of these altered miRNAs was independently validated by qRT-PCR, which included 18 supplementary TT-UMP (eight WDT-UMP and ten FT-UMP). Supervised clustering techniques were used to predict the first 42 samples. Based on the four possible outcomes (FTA, C-PTC, FV-PTC, and FTC), about 80% of FTA and C-PTC and 50% of FV-PTC and FTC samples were correctly assigned. Analysis of the independent set of 18 WDT-UMP by quantitative RT-PCR for the selection of the six most discriminating miRNAs was unable to separate FT-UMP from WDT-UMP, suggesting that the miRNA signature is insufficient in characterizing these two clinical entities. We conclude that considering FT-UMP and WDT-UMP as distinct and specific clinical entities may improve the diagnosis of WDT of the thyroid gland. In this context, a small set of miRNAs (i.e. miR-7, miR-146a, miR-146b, miR-200b, miR-221, and miR-222) appears to be useful, though not sufficient per se, in distinguishing TT-UMP from other WDT of the thyroid gland.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21778212     DOI: 10.1530/ERC-10-0283

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  12 in total

Review 1.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

2.  Comparison of the clinicopathological behavior of the follicular variant of papillary thyroid carcinoma and classical papillary thyroid carcinoma: A systematic review and meta-analysis.

Authors:  Jing Yang; Yanping Gong; Shuping Yan; Qingquan Shi; Jingqiang Zhu; Zhihui Li; Qiang Chen; Rixiang Gong
Journal:  Mol Clin Oncol       Date:  2015-04-06

3.  Expression and clinicopathological role of miR146a in thyroid follicular carcinoma.

Authors:  Elisa Pignatti; Eleonora Vighi; Elisa Magnani; Elda Kara; Luca Roncati; Antonino Maiorana; Daniele Santi; Bruno Madeo; Katia Cioni; Cesare Carani; Vincenzo Rochira; Manuela Simoni; Giulia Brigante
Journal:  Endocrine       Date:  2019-01-30       Impact factor: 3.633

4.  HMGB1-Induced Cross Talk between PTEN and miRs 221/222 in Thyroid Cancer.

Authors:  S Mardente; E Mari; I Massimi; F Fico; A Faggioni; F Pulcinelli; A Antonaci; A Zicari
Journal:  Biomed Res Int       Date:  2015-05-27       Impact factor: 3.411

5.  Molecular classification of thyroid lesions by combined testing for miRNA gene expression and somatic gene alterations.

Authors:  Dennis Wylie; Sylvie Beaudenon-Huibregtse; Brian C Haynes; Thomas J Giordano; Emmanuel Labourier
Journal:  J Pathol Clin Res       Date:  2016-02-08

Review 6.  miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma.

Authors:  Emanuela Minna; Paola Romeo; Matteo Dugo; Loris De Cecco; Katia Todoerti; Silvana Pilotti; Federica Perrone; Ettore Seregni; Luca Agnelli; Antonino Neri; Angela Greco; Maria Grazia Borrello
Journal:  Oncotarget       Date:  2016-03-15

Review 7.  miRNA expression and function in thyroid carcinomas: a comparative and critical analysis and a model for other cancers.

Authors:  Manuel Saiselet; Jaime M Pita; Alice Augenlicht; Geneviève Dom; Maxime Tarabichi; Danai Fimereli; Jacques E Dumont; Vincent Detours; Carine Maenhaut
Journal:  Oncotarget       Date:  2016-08-09

8.  Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.

Authors:  Aisen Zhang; Cheng Wang; Hui Lu; Xi Chen; Yi Ba; Chunni Zhang; Chen-Yu Zhang
Journal:  Dis Markers       Date:  2019-09-16       Impact factor: 3.434

9.  miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma.

Authors:  Emanuela Minna; Paola Romeo; Loris De Cecco; Matteo Dugo; Giuliana Cassinelli; Silvana Pilotti; Debora Degl'Innocenti; Cinzia Lanzi; Patrizia Casalini; Marco A Pierotti; Angela Greco; Maria Grazia Borrello
Journal:  Oncotarget       Date:  2014-05-15

10.  MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.

Authors:  Sandra Lassalle; Joséphine Zangari; Alexandra Popa; Marius Ilie; Véronique Hofman; Elodie Long; Martine Patey; Frédérique Tissier; Geneviève Belléannée; Hélène Trouette; Bogdan Catargi; Isabelle Peyrottes; Jean-Louis Sadoul; Olivier Bordone; Christelle Bonnetaud; Catherine Butori; Alexandre Bozec; Nicolas Guevara; José Santini; Imène Sarah Hénaoui; Géraldine Lemaire; Olivier Blanck; Philippe Vielh; Pascal Barbry; Bernard Mari; Patrick Brest; Paul Hofman
Journal:  Oncotarget       Date:  2016-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.